Physician profile
Mark Vranicar
NPI 1841215647
$2,903.66
in general payments reported to CMS, 2019-2025
9 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Pediatric Cardiology provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.35 · 2022: $1,075 · 2023: $174 · 2024: $1,348 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $965 · Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $964.81 |
| Food and Beverage | $771.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $1,265.57 | 2023-2024 | Artis Icono Biplane, Artis Icono Floor, Magnetom Vida |
| Abbott Laboratories | $1,216.98 | 2021-2025 | Amplatzer Piccolo, Amplatzer |
| B. Braun Interventional Systems INC. | $126.64 | 2022-2025 | Cp Stent, Na |
| W. L. Gore & Associates, INC. | $95.22 | 2023-2025 | Gore Cardioform Septal Occluder, Gore Cardioform Asd Occluder |
| Philips North America LLC | $82.92 | 2022 | |
| Vital Connect, INC | $53.12 | 2023-2025 | Vitalpatch Rtm |
| Boston Scientific Corporation | $33.41 | 2025 | Baylis Medical Company Radiofrequency Puncture Generator |
| Azurity Pharmaceuticals, INC. | $29.80 | 2024 | Katerzia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vranicar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.